Literature DB >> 23482850

Blockade of Autocrine TGF-β Signaling Inhibits Stem Cell Phenotype, Survival, and Metastasis of Murine Breast Cancer Cells.

Zhao Liu1, Abhik Bandyopadhyay, Robert W Nichols, Long Wang, Andrew P Hinck, Shui Wang, Lu-Zhe Sun.   

Abstract

Transforming growth factor beta (TGF-β) signaling has been implicated in driving tumor progression and metastasis by inducing stem cell-like features in some human cancer cell lines. In this study, we have utilized a novel murine cell line NMuMG-ST, which acquired cancer stem cell (CSC) phenotypes during spontaneous transformation of the untransformed murine mammary cell line NMuMG, to investigate the role of autocrine TGF-β signaling in regulating their survival, metastatic ability, and the maintenance of cancer stem cell characteristics. We have retrovirally transduced a dominant-negative TGF-β type II receptor (DNRII) into the NMuMG-ST cell to abrogate autocrine TGF-β signaling. The expression of DNRII reduced TGF-β sensitivity of the NMuMG-ST cells in various cell-based assays. The blockade of autocrine TGF-β signaling reduced the ability of the cell to grow anchorage-independently and to resist serum deprivation-induced apoptosis. These phenotypes were associated with reduced levels of active and phosphorylated AKT and ERK, and Gli1 expression suggesting that these pathways contribute to the growth and survival of this model system. More interestingly, the abrogation of autocrine TGF-β signaling also led to the attenuation of several features associated with mammary stem cells including epithelial-mesenchymal transition, mammosphere formation, and expression of stem cell markers. When xenografted in athymic nude mice, the DNRII cells were also found to undergo apoptosis and induced significantly lower lung metastasis burden than the control cells even though they formed similar size of xenograft tumors. Thus, our results indicate that autocrine TGF-β signaling is involved in the maintenance and survival of stem-like cell population resulting in the enhanced metastatic ability of the murine breast cancer cells.

Entities:  

Keywords:  Apoptosis; Autocrine TGF-beta; Breast cancer; Cancer stem cell; Lung metastasis

Year:  2012        PMID: 23482850      PMCID: PMC3593047          DOI: 10.4172/2157-7633.1000116

Source DB:  PubMed          Journal:  J Stem Cell Res Ther


  64 in total

1.  Analyses of microsatellite instability and the transforming growth factor-beta receptor type II gene mutation in sporadic breast cancer and their correlation with clinicopathological features.

Authors:  S Tomita; S Deguchi; T Miyaguni; Y Muto; T Tamamoto; T Toda
Journal:  Breast Cancer Res Treat       Date:  1999-01       Impact factor: 4.872

2.  Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway.

Authors:  Yibin Kang; Wei He; Shaun Tulley; Gaorav P Gupta; Inna Serganova; Chang-Rung Chen; Katia Manova-Todorova; Ronald Blasberg; William L Gerald; Joan Massagué
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-19       Impact factor: 11.205

3.  Transforming growth factor beta 1 suppresses genomic instability independent of a G1 arrest, p53, and Rb.

Authors:  A B Glick; W C Weinberg; I H Wu; W Quan; S H Yuspa
Journal:  Cancer Res       Date:  1996-08-15       Impact factor: 12.701

Review 4.  TGFbeta in Cancer.

Authors:  Joan Massagué
Journal:  Cell       Date:  2008-07-25       Impact factor: 41.582

5.  Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models.

Authors:  Abhik Bandyopadhyay; Long Wang; Joseph Agyin; Yuping Tang; Shu Lin; I-Tien Yeh; Keya De; Lu-Zhe Sun
Journal:  PLoS One       Date:  2010-04-28       Impact factor: 3.240

Review 6.  ALDH1 as a functional marker of cancer stem and progenitor cells.

Authors:  Julie Douville; Raymond Beaulieu; Danuta Balicki
Journal:  Stem Cells Dev       Date:  2009 Jan-Feb       Impact factor: 3.272

7.  Sustained TGF beta exposure suppresses Smad and non-Smad signalling in mammary epithelial cells, leading to EMT and inhibition of growth arrest and apoptosis.

Authors:  A Gal; T Sjöblom; L Fedorova; S Imreh; H Beug; A Moustakas
Journal:  Oncogene       Date:  2007-08-27       Impact factor: 9.867

Review 8.  Cancer stem cells in breast: current opinion and future challenges.

Authors:  Emmanuelle Charafe-Jauffret; Florence Monville; Christophe Ginestier; Gabriela Dontu; Daniel Birnbaum; Max S Wicha
Journal:  Pathobiology       Date:  2008-06-10       Impact factor: 4.342

9.  Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas.

Authors:  W M Grady; A Rajput; L Myeroff; D F Liu; K Kwon; J Willis; S Markowitz
Journal:  Cancer Res       Date:  1998-07-15       Impact factor: 12.701

10.  Relationship between tamoxifen-induced transforming growth factor beta 1 expression, cytostasis and apoptosis in human breast cancer cells.

Authors:  R R Perry; Y Kang; B R Greaves
Journal:  Br J Cancer       Date:  1995-12       Impact factor: 7.640

View more
  14 in total

Review 1.  Pharmacological targets of breast cancer stem cells: a review.

Authors:  Sai Kiran S S Pindiprolu; Praveen T Krishnamurthy; Pavan Kumar Chintamaneni
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-02-23       Impact factor: 3.000

2.  Activation of IL-8 via PI3K/Akt-dependent pathway is involved in leptin-mediated epithelial-mesenchymal transition in human breast cancer cells.

Authors:  Lin Wang; Cuiping Tang; Hong Cao; Kuangfa Li; Xueli Pang; Liang Zhong; Weiqi Dang; Hao Tang; Yunxiu Huang; Lan Wei; Min Su; Tingmei Chen
Journal:  Cancer Biol Ther       Date:  2015-06-29       Impact factor: 4.742

3.  Osteopontin mediates an MZF1-TGF-β1-dependent transformation of mesenchymal stem cells into cancer-associated fibroblasts in breast cancer.

Authors:  C E Weber; A N Kothari; P Y Wai; N Y Li; J Driver; M A C Zapf; C A Franzen; G N Gupta; C Osipo; A Zlobin; W K Syn; J Zhang; P C Kuo; Z Mi
Journal:  Oncogene       Date:  2014-12-22       Impact factor: 9.867

Review 4.  Targeting cancer stem cells by using the nanoparticles.

Authors:  In-Sun Hong; Gyu-Beom Jang; Hwa-Yong Lee; Jeong-Seok Nam
Journal:  Int J Nanomedicine       Date:  2015-09-10

5.  Blockage of TGFβ-SMAD2 by demethylation-activated miR-148a is involved in caffeic acid-induced inhibition of cancer stem cell-like properties in vitro and in vivo.

Authors:  Yuan Li; Fei Jiang; Lijun Chen; Ye Yang; Shuyuan Cao; Yuting Ye; Xingxing Wang; Juan Mu; Zhong Li; Lei Li
Journal:  FEBS Open Bio       Date:  2015-05-29       Impact factor: 2.693

Review 6.  The role of high mobility group box 1 in innate immunity.

Authors:  Shin-Ae Lee; Man Sup Kwak; Sol Kim; Jeon-Soo Shin
Journal:  Yonsei Med J       Date:  2014-09       Impact factor: 2.759

7.  Genome-wide microarray expression and genomic alterations by array-CGH analysis in neuroblastoma stem-like cells.

Authors:  Raquel Ordóñez; Gabriel Gallo-Oller; Soledad Martínez-Soto; Sheila Legarra; Noémie Pata-Merci; Justine Guegan; Giselle Danglot; Alain Bernheim; Bárbara Meléndez; Juan A Rey; Javier S Castresana
Journal:  PLoS One       Date:  2014-11-13       Impact factor: 3.240

Review 8.  Application of Nanotechnology in Targeting of Cancer Stem Cells: A Review.

Authors:  Fatemeh Asghari; Rahele Khademi; Faezeh Esmaeili Ranjbar; Ziba Veisi Malekshahi; Reza Faridi Majidi
Journal:  Int J Stem Cells       Date:  2019-07-31       Impact factor: 2.500

Review 9.  The roles of FOXM1 in pancreatic stem cells and carcinogenesis.

Authors:  Ming Quan; Peipei Wang; Jiujie Cui; Yong Gao; Keping Xie
Journal:  Mol Cancer       Date:  2013-12-10       Impact factor: 27.401

Review 10.  Breast Cancer Stem Cells.

Authors:  Judy S Crabtree; Lucio Miele
Journal:  Biomedicines       Date:  2018-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.